Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomas

• DOI: 10.3389/fgene.2022.873655
• Publication Date: 2022-11-16T07:03:01Z
• Authors: Hesong Wang; Yanyan Feng; Yuxiang Zhang; Ting Wang; Heng Xu; Yuxing Zhi; Yuyin Feng; Lichun Tian; Kai Yuan
• Keywords: 0301 basic medicine; 03 medical and health sciences; Siglec10; glioma; Genetics; mechanism; biomarker; prognosis; QH426-470; 3. Good health

Glioma is a type of tumor occurring in the central nervous system. In recent decades, specific gene mutations and molecular aberrations have been used to conduct the glioma classification and clinical decisions. Siglec10 is a member of the sialic acid-binding immunoglobulin superfamily. In this study, we investigated the expression and functions of siglec10 in gliomas. We analyzed the siglec10 expression in glioma patients with immunohistochemical (IHC) staining and evaluated the survival prognosis. The high siglec10 expression had a shorter survival prognosis than the low siglec10 expression in patients, especially in malignant gliomas. Bioinformatic datasets, including TCGA and CGGA, validated the IHC results and discovered the expression of siglec10 was higher in the malignant subtype than a benign subtype of gliomas. So, siglec10 is associated with the poor prognosis of gliomas. Furthermore, the related mechanisms of siglec10 in gliomas were investigated by functional enrichment analysis, including GSEA, GO, and KEGG analysis. Siglec10 was correlated with inflammatory mediators, inflammatory cells, and inflammatory pathways in gliomas. Siglec10 might take part in the immune response in the tumor microenvironment to induce glioma’s progression and metastasis. This study showed siglec10 was a biomarker in glioma, and it might be the potential target of glioma immunotherapy in the future.